chlorpromazine has been researched along with Disease Models, Animal in 121 studies
Chlorpromazine: The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.
chlorpromazine : A substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropanamine moiety.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To analyze the influence of chlorpromazine on renal histology of rats submitted to ischemia and reperfusion injury." | 7.83 | Influence of chlorpromazine on renal histology of rats submitted to ischemia and reperfusion injury. ( Brenny, T; Czeczko, NG; Foiatto, JC; Gomes, RP; Malafaia, O; Oliveira, AM; Wietzikoski, EG, 2016) |
| "We developed a novel murine candidiasis model of the gastrointestinal tract using N-acetylglucosamine ( GlcNAc ) as a tool to aggravate symptoms." | 7.81 | A Novel Murine Candidiasis Model with Severe Colonization in the Stomach Induced by N-acetylglucosamine-treatment and Its Scoring System Based on Local Characteristic Stomach Symptoms. ( Abe, S; Ishijima, SA, 2015) |
| "L-sulpiride, at a dose of 4 mg/kg, essentially abolished motion-induced emesis in a group of 6 squirrel monkeys undergoing horizontal rotation at 25 rpm, a terrestrial model of space motion sickness (SMS)." | 7.67 | The anti-emetic properties of 1-sulpiride in a ground-based model of space motion sickness. ( Brizzee, KR; Miller, JD, 1987) |
| "Intrahepatic cholestasis associated with hyperbilirubinemia was induced by the simultaneous administration of ethynyl estradiol (EE) and chlorpromazine hydrochloride (CPZ) for 7 days to female Sprague-Dawley rats." | 7.66 | Intrahepatic cholestasis and hyperbilirubinemia in ethynyl estradiol and chlorpromazine-treated rats. ( Obata, T, 1983) |
| "Schizophrenia is a chronic mental disorder reported to compromise about 1% of the world's population." | 5.48 | Advantages of the Alpha-lipoic Acid Association with Chlorpromazine in a Model of Schizophrenia Induced by Ketamine in Rats: Behavioral and Oxidative Stress evidences. ( Cysne Filho, FMS; de Almeida, JC; de Sousa, CNS; Diniz, DDS; Macêdo, D; Patrocínio, CFV; Patrocínio, MCA; Sampaio, LRL; Vasconcelos, SMM, 2018) |
| "Schizophrenia is characterized by behavioral symptoms, brain function impairments and electroencephalographic (EEG) changes." | 5.46 | Electroencephalographic study of chlorpromazine alone or combined with alpha-lipoic acid in a model of schizophrenia induced by ketamine in rats. ( Barbosa, TM; Borges, LTN; Gularte, VN; Lima, RF; Macêdo, D; Matos, NCB; Oliveira, MN; Patrocínio, MCA; Sampaio, LRL; Vale, OCD; Vasconcelos, SMM, 2017) |
| "In both the CPZ-treated and nontreated groups, ischemia induced a decline in muscle glycogen content, with a corresponding increase in muscle lactate and a decrease in mitochondrial respiratory control ratio." | 5.32 | Lack of chlorpromazine effect on skeletal muscle metabolism after ischemia and a short reperfusion period. ( Cherri, J; Massuda, CA; Piccinato, CE; Salles Roselino, JE, 2004) |
| "Ebselen was the only treatment able to decrease MDA concentration to control values, exerting an effect similar to that elicited by L-NAME on the rest of the parameters tested." | 5.31 | Role of oxygen and nitrogen species in experimental uveitis: anti-inflammatory activity of the synthetic antioxidant ebselen. ( Bosch-Morell, F; Díaz-Llopis, M; Johnsen-Soriano, S; Marín, N; Rodriguez-Galietero, A; Romá, J; Romero, B; Romero, FJ, 2002) |
| "QUIN seizures showed particular sensitivity to carbamazepine (5 mg/kg) but were resistant to diphenylhydantoin unless a relatively high dose was used (100 mg/kg)." | 5.27 | Anticonvulsant drugs effective against human temporal lobe epilepsy prevent seizures but not neurotoxicity induced in rats by quinolinic acid: electroencephalographic, behavioral and histological assessments. ( Samanin, R; Tullii, M; Vezzani, A; Wu, HQ, 1986) |
| "When chlorpromazine hydrochloride was infused at three doses (2." | 5.26 | Effects of chlorpromazine hydrochloride on bile salt synthesis, bile formation and biliary lipid secretion in the rhesus monkey: a model for chlorpromazine-induced cholestasis. ( Carey, MC; Ros, E; Small, DM, 1979) |
| "To analyze the influence of chlorpromazine on renal histology of rats submitted to ischemia and reperfusion injury." | 3.83 | Influence of chlorpromazine on renal histology of rats submitted to ischemia and reperfusion injury. ( Brenny, T; Czeczko, NG; Foiatto, JC; Gomes, RP; Malafaia, O; Oliveira, AM; Wietzikoski, EG, 2016) |
| "We developed a novel murine candidiasis model of the gastrointestinal tract using N-acetylglucosamine ( GlcNAc ) as a tool to aggravate symptoms." | 3.81 | A Novel Murine Candidiasis Model with Severe Colonization in the Stomach Induced by N-acetylglucosamine-treatment and Its Scoring System Based on Local Characteristic Stomach Symptoms. ( Abe, S; Ishijima, SA, 2015) |
| "A simple method to establish a murine esophageal candidiasis model that displayed characteristic symptoms of the condition was developed using the sedative agent, chlorpromazine." | 3.74 | A murine model of esophageal candidiasis with local characteristic symptoms. ( Abe, S; Hisajima, T; Hu, W; Ishibashi, H; Nishiyama, Y; Yamaguchi, H, 2007) |
| "To evaluate the influence of chlorpromazine (CPZ) on renal function and lipid peroxidation in a rat model of kidney ischemia/reperfusion injury." | 3.74 | Renal ischemia and reperfusion injury: influence of chorpromazine on renal function and lipid peroxidation. ( Carvalho, RM; Celini, FM; Cologna, AJ; Martins, AC; Suaid, HJ; Tirapelli, LF; Tucci Junior, S, 2008) |
| " This exhibited features similar to human lupus and was induced by injecting mice either with the H308 monoclonal antibody specific to NPA, with sera from mice which already had developed the autoimmune disease, or with liposomes treated with the NPA inductors chlorpromazine or procainamide; or with these NPA inductors alone." | 3.72 | Antibodies to non-bilayer phospholipid arrangements induce a murine autoimmune disease resembling human lupus. ( Baeza, I; Campos, B; Farfán, N; Flores-Romo, L; Hernández-Pando, R; Ibáñez, M; Lara, M; Leyva, E; Orozco, H; Wong, C, 2004) |
| "Chlorpromazine mitigates the development of zymosan-induced MODS, possibly by reducing macrophage TNF-alpha production." | 3.70 | Chlorpromazine down-regulates tumor necrosis factor-alpha and attenuates experimental multiple organ dysfunction syndrome in mice. ( Goris, RJ; Hendriks, T; Jansen, MJ; Knapen, MF; van der Meer, JW; van Kempen, LC, 1998) |
| "L-sulpiride, at a dose of 4 mg/kg, essentially abolished motion-induced emesis in a group of 6 squirrel monkeys undergoing horizontal rotation at 25 rpm, a terrestrial model of space motion sickness (SMS)." | 3.67 | The anti-emetic properties of 1-sulpiride in a ground-based model of space motion sickness. ( Brizzee, KR; Miller, JD, 1987) |
| "Intrahepatic cholestasis associated with hyperbilirubinemia was induced by the simultaneous administration of ethynyl estradiol (EE) and chlorpromazine hydrochloride (CPZ) for 7 days to female Sprague-Dawley rats." | 3.66 | Intrahepatic cholestasis and hyperbilirubinemia in ethynyl estradiol and chlorpromazine-treated rats. ( Obata, T, 1983) |
| "We have induced photoallergic contact dermatitis in mice to 3,3',4',5 tetrachlorosalicylanilide (TCSA), chlorpromazine and 6-methylcoumarin." | 3.66 | Experimental photoallergic contact dermatitis: a mouse model. ( Kaidbey, K; Maguire, HC, 1982) |
| "It has been reported that intraventricular injection of chlorpromazine methiodide (CPZMI), a quaternary ammonium derivative of chlorpromazine, in rats induces abnormal, twisting postures which may serve as an experimental model of the human movement disorder dystonia." | 3.66 | Electroencephalographic studies of chlorpromazine methiodide and somatostatin-induced barrel rotation in rats. ( Burke, RE; Fahn, S, 1983) |
| "Schizophrenia is an incurable neuropsychiatric disorder managed mostly by treatment of the patients with antipsychotics." | 2.53 | Employing proteomics to unravel the molecular effects of antipsychotics and their role in schizophrenia. ( Cassoli, JS; Guest, PC; Martins-de-Souza, D; Santana, AG, 2016) |
| "Acute dystonia can also be reliably induced in many primate species by neuroleptic treatment with comparable time course, symptomatology and pharmacological characteristics to those observed in man." | 2.37 | Acute dystonia induced by neuroleptic drugs. ( Jenner, P; Marsden, CD; Rupniak, NM, 1986) |
| "Schizophrenia is a chronic mental disorder reported to compromise about 1% of the world's population." | 1.48 | Advantages of the Alpha-lipoic Acid Association with Chlorpromazine in a Model of Schizophrenia Induced by Ketamine in Rats: Behavioral and Oxidative Stress evidences. ( Cysne Filho, FMS; de Almeida, JC; de Sousa, CNS; Diniz, DDS; Macêdo, D; Patrocínio, CFV; Patrocínio, MCA; Sampaio, LRL; Vasconcelos, SMM, 2018) |
| "Parkinsonism is characterized by rest tremor, inflexibility, balance debilitation, slow motion and dementia." | 1.48 | Anticataleptic activity of Zamzam water in chlorpromazine induced animal model of Parkinson disease. ( Ikram, R; Riaz, B; Sikandar, B, 2018) |
| "Schizophrenia is characterized by behavioral symptoms, brain function impairments and electroencephalographic (EEG) changes." | 1.46 | Electroencephalographic study of chlorpromazine alone or combined with alpha-lipoic acid in a model of schizophrenia induced by ketamine in rats. ( Barbosa, TM; Borges, LTN; Gularte, VN; Lima, RF; Macêdo, D; Matos, NCB; Oliveira, MN; Patrocínio, MCA; Sampaio, LRL; Vale, OCD; Vasconcelos, SMM, 2017) |
| "The ability of SNE to cause catalepsy in naïve mice as well as its effect on haloperidol-induced catalepsy was assessed." | 1.46 | Extract of Synedrella nodiflora (L) Gaertn exhibits antipsychotic properties in murine models of psychosis. ( Adjei, S; Amoateng, P; Bekoe, EO; Karikari, TK; Kombian, SB; Kukuia, KKE; Osei-Safo, D, 2017) |
| "Systemic lupus erythematosus is characterized by dysregulated activation of T and B cells and autoantibodies to nuclear antigens and, in some cases, lipid antigens." | 1.42 | Nonbilayer Phospholipid Arrangements Are Toll-Like Receptor-2/6 and TLR-4 Agonists and Trigger Inflammation in a Mouse Model Resembling Human Lupus. ( Astudillo, H; Baeza, I; España, L; Estrada-García, I; Estrada-Parra, S; Flores-Romo, L; Landa, C; Reséndiz, A; Serafín-López, J; Tescucano, A; Wong, C; Wong-Baeza, C, 2015) |
| "The extrapyramidal side effect of catalepsy was tested based on the ability of the extracts to alter the duration of akinesia in mice placed on a vertical wrapped string." | 1.38 | Antipsychotic property of aqueous and ethanolic extracts of Lonchocarpus cyanescens (Schumach and Thonn.) Benth. (Fabaceae) in rodents. ( Shonibare, ET; Sonibare, MA; Umukoro, S, 2012) |
| "During drug development, seizure threshold tests are widely used to identify potential proconvulsant activity of investigational drugs." | 1.38 | Striking differences in proconvulsant-induced alterations of seizure threshold in two rat models. ( Bankstahl, JP; Bankstahl, M; Bloms-Funke, P; Löscher, W, 2012) |
| "In both the CPZ-treated and nontreated groups, ischemia induced a decline in muscle glycogen content, with a corresponding increase in muscle lactate and a decrease in mitochondrial respiratory control ratio." | 1.32 | Lack of chlorpromazine effect on skeletal muscle metabolism after ischemia and a short reperfusion period. ( Cherri, J; Massuda, CA; Piccinato, CE; Salles Roselino, JE, 2004) |
| "In the catalepsy test, quetiapine only weakly induced catalepsy at the highest dose of 100 mg/kg, whereas risperidone, chlorpromazine, and haloperidol dose-dependently induced catalepsy with ED50 values of 0." | 1.32 | Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine. ( Matsuoka, N; Mutoh, S; Shirakawa, K; Tada, M, 2004) |
| "Ebselen was the only treatment able to decrease MDA concentration to control values, exerting an effect similar to that elicited by L-NAME on the rest of the parameters tested." | 1.31 | Role of oxygen and nitrogen species in experimental uveitis: anti-inflammatory activity of the synthetic antioxidant ebselen. ( Bosch-Morell, F; Díaz-Llopis, M; Johnsen-Soriano, S; Marín, N; Rodriguez-Galietero, A; Romá, J; Romero, B; Romero, FJ, 2002) |
| "Gliotoxin treatment significantly reduced the number of activated stellate cells and mean thickness of bridging fibrotic septae in livers from rats treated with carbon tetrachloride." | 1.31 | Gliotoxin stimulates the apoptosis of human and rat hepatic stellate cells and enhances the resolution of liver fibrosis in rats. ( Arthur, MJ; Iredale, JP; Issa, R; Mann, DA; Murray, GI; Primrose, JN; Smart, DE; Trim, N; Wright, MC, 2001) |
| "Pretreatment with propranolol (10 mg/kg), a 5-HT(1A) receptor antagonist as well as a beta-blocker, and dantrolene (20 mg/kg), a peripheral muscle relaxant, did not prevent the death of the animals, even though these two drugs suppressed the increase in rectal temperature to some extent." | 1.31 | Potent serotonin (5-HT)(2A) receptor antagonists completely prevent the development of hyperthermia in an animal model of the 5-HT syndrome. ( Katoh, S; Nisijima, K; Yoshino, T; Yui, K, 2001) |
| "Spinal cord ischemia was obtained by clamping the abdominal aorta caudally to the renal arteries for 30 min, after which it was released and the animals were observed for a period of 48 hrs." | 1.31 | The protective action of chlorpromazine on the spinal cord of rabbits submitted to ischemia and reperfusion is dose-dependent. ( Alves, P; Barbieri-Neto, J; Mazzetto, SA; Sader, AA; Sader, SL; Vanni, JC, 2002) |
| "Both prazosin and pentolinium elicited orthostatic hypotension under all four anesthetic conditions." | 1.30 | A rabbit model for evaluation of chlorpromazine-induced orthostatic hypotension. ( Kato, H; Kurihara, J; Okubo, Y; Suzuki, S; Takata, Y, 1999) |
| " Vasoconstriction was induced by epinephrine in all groups in a dose-response fashion." | 1.30 | Vascular effects of epinephrine, lisinopril, and chlorpromazine in diabetic and non-diabetic rats. ( Aygit, AC; Ayhan, MS; Demiralay, A; Yildirim, I, 1999) |
| "Cyproheptadine and verapamil were not effective in reversing chloroquine resistance and probable drug toxicity was observed with these drugs in combination with chloroquine." | 1.29 | Reversal of Plasmodium falciparum resistance to chloroquine in Panamanian Aotus monkeys. ( Kyle, DE; Milhous, WK; Rossan, RN, 1993) |
| "Chlorpromazine (CPZ) has been used extensively in the treatment of psychiatric disorders, and has recently been shown to possess systemic anti-inflammatory properties as well." | 1.28 | The effect of chlorpromazine on endotoxin-induced uveitis in the Lewis rat. ( Chan, CC; Cordella-Miele, E; Gery, I; Kasner, L, 1992) |
| "The chlorpromazine group was similar to the haloperidol group." | 1.28 | Conditioned drug effects of pimozide, haloperidol and chlorpromazine on methamphetamine-induced behavior. ( Miyamoto, K, 1990) |
| " Chlorpromazine, administered intramuscularly on 3 successive days following the dual infection in 8 K88ac susceptible pigs, in a dosage of 2 and 1." | 1.28 | Effect of chlorpromazine on experimental diarrhoea in just-weaned piglets. ( Cools, V; Cox, E; Houvenaghel, A, 1989) |
| "QUIN seizures showed particular sensitivity to carbamazepine (5 mg/kg) but were resistant to diphenylhydantoin unless a relatively high dose was used (100 mg/kg)." | 1.27 | Anticonvulsant drugs effective against human temporal lobe epilepsy prevent seizures but not neurotoxicity induced in rats by quinolinic acid: electroencephalographic, behavioral and histological assessments. ( Samanin, R; Tullii, M; Vezzani, A; Wu, HQ, 1986) |
| "Chlorpromazine pretreatment (15 mg X kg-1 intravenously) reduced the increase in nonsedimentable cathepsin D activity slightly, but no appreciable protective effect on the anatomical redistribution of the enzyme or the development of ultrastructural signs of necrosis could be detected." | 1.27 | Influence of chlorpromazine on lysosomal alterations during myocardial ischaemia. ( Chien, KR; Crie, JS; Decker, RS; Wildenthal, K, 1983) |
| "Rats treated with chlorpromazine (CPZ) (1 mg/kg/day i." | 1.27 | Amphetamine and chlorpromazine modify cerebral insulin levels in rats. ( Benedi, J; Cantón, R; Grande, C; Manzanares, J; Zaragozá, F, 1988) |
| "In a typical experiment of photosensitization to systemic sulfanilamide, the experimental group had a mean increase in ear thickness of 6." | 1.27 | Experimental photoallergy to systemic drugs. ( Giudici, PA; Maguire, HC, 1985) |
| "Chlorpromazine that depresses decerebrate rigidity in a dose-related fashion requires 1." | 1.26 | Suppression of decerebrate rigidity by phenytoin and chlorpromazine. ( Anderson, RJ; Raines, A, 1976) |
| " After the drug injection, however, the duration increased significantly with increasing heart rate, the effect depending on the injected dosage (r==0." | 1.26 | The prolongation of QRS-duration resulting from delayed recovery of ventricular excitability. A new mechanism for intraventricular conduction disturbance. A preliminary note. ( Arita, M; Nagamoto, Y; Saikawa, T, 1976) |
| "When chlorpromazine hydrochloride was infused at three doses (2." | 1.26 | Effects of chlorpromazine hydrochloride on bile salt synthesis, bile formation and biliary lipid secretion in the rhesus monkey: a model for chlorpromazine-induced cholestasis. ( Carey, MC; Ros, E; Small, DM, 1979) |
| "Rats with ablated frontal sensorimotor cortex and one with ablated sensorimotor connections to forebrain showed more vacuous chewing movements following 6-week chronic administration of a neuroleptic than did occipitally damaged rats or normal controls who were treated in the same way." | 1.26 | Oral dyskinesia in brain-damaged rats withdrawn from a neuroleptic: implication for models of tardive dyskinesia. ( Glassman, HN; Glassman, RB, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 66 (54.55) | 18.7374 |
| 1990's | 14 (11.57) | 18.2507 |
| 2000's | 17 (14.05) | 29.6817 |
| 2010's | 20 (16.53) | 24.3611 |
| 2020's | 4 (3.31) | 2.80 |
| Authors | Studies |
|---|---|
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Liu, X | 1 |
| Fan, T | 1 |
| Guan, J | 1 |
| Luo, A | 1 |
| Yu, Y | 1 |
| Chen, D | 1 |
| Mao, B | 1 |
| Jiang, H | 1 |
| Liu, W | 1 |
| Lin, X | 1 |
| Xu, P | 1 |
| Tian, Y | 1 |
| Xiao, H | 1 |
| Dong, X | 1 |
| Wang, S | 1 |
| Khan, SS | 1 |
| Ikram, R | 2 |
| Naeem, S | 1 |
| Khatoon, H | 1 |
| Anser, H | 1 |
| Sikander, B | 1 |
| Jiang, MD | 1 |
| Zheng, Y | 1 |
| Wang, JL | 1 |
| Wang, YF | 1 |
| Amoateng, P | 1 |
| Adjei, S | 1 |
| Osei-Safo, D | 1 |
| Kukuia, KKE | 1 |
| Bekoe, EO | 1 |
| Karikari, TK | 1 |
| Kombian, SB | 1 |
| An, H | 1 |
| Duan, Y | 1 |
| Wu, D | 1 |
| Yip, J | 1 |
| Elmadhoun, O | 1 |
| Wright, JC | 1 |
| Shi, W | 1 |
| Liu, K | 1 |
| He, X | 1 |
| Shi, J | 1 |
| Jiang, F | 1 |
| Ji, X | 1 |
| Ding, Y | 1 |
| Sampaio, LRL | 2 |
| Cysne Filho, FMS | 1 |
| de Almeida, JC | 1 |
| Diniz, DDS | 1 |
| Patrocínio, CFV | 1 |
| de Sousa, CNS | 1 |
| Patrocínio, MCA | 2 |
| Macêdo, D | 2 |
| Vasconcelos, SMM | 2 |
| Zárate-Neira, LÁ | 1 |
| Sánchez-Barbosa, S | 1 |
| Pedroza-Torres, A | 1 |
| Reséndiz-Mora, A | 1 |
| Wong, C | 3 |
| Baeza, I | 3 |
| Pérez-Plasencia, C | 1 |
| Wong-Baeza, C | 2 |
| Riaz, B | 1 |
| Sikandar, B | 1 |
| Kurauchi, Y | 1 |
| Yoshimaru, Y | 1 |
| Kajiwara, Y | 1 |
| Yamada, T | 1 |
| Matsuda, K | 1 |
| Hisatsune, A | 1 |
| Seki, T | 1 |
| Katsuki, H | 1 |
| Baloch, J | 1 |
| Sohail, MF | 1 |
| Sarwar, HS | 1 |
| Kiani, MH | 1 |
| Khan, GM | 1 |
| Jahan, S | 1 |
| Rafay, M | 1 |
| Chaudhry, MT | 1 |
| Yasinzai, M | 1 |
| Shahnaz, G | 1 |
| Basta-Kaim, A | 1 |
| Szczęsny, E | 1 |
| Leśkiewicz, M | 1 |
| Głombik, K | 1 |
| Slusarczyk, J | 1 |
| Budziszewska, B | 1 |
| Regulska, M | 1 |
| Kubera, M | 1 |
| Nowak, W | 1 |
| Wędzony, K | 1 |
| Lasoń, W | 1 |
| Eun, JW | 1 |
| Bae, HJ | 1 |
| Shen, Q | 1 |
| Park, SJ | 1 |
| Kim, HS | 1 |
| Shin, WC | 1 |
| Yang, HD | 1 |
| Jin, CY | 1 |
| You, JS | 1 |
| Kang, HJ | 1 |
| Kim, H | 1 |
| Ahn, YM | 1 |
| Park, WS | 1 |
| Lee, JY | 1 |
| Nam, SW | 1 |
| Tescucano, A | 1 |
| Astudillo, H | 1 |
| Reséndiz, A | 1 |
| Landa, C | 1 |
| España, L | 1 |
| Serafín-López, J | 1 |
| Estrada-García, I | 1 |
| Estrada-Parra, S | 1 |
| Flores-Romo, L | 2 |
| Ishijima, SA | 1 |
| Abe, S | 3 |
| Cassoli, JS | 1 |
| Guest, PC | 1 |
| Santana, AG | 1 |
| Martins-de-Souza, D | 1 |
| Borges, LTN | 1 |
| Barbosa, TM | 1 |
| Matos, NCB | 1 |
| Lima, RF | 1 |
| Oliveira, MN | 1 |
| Gularte, VN | 1 |
| Vale, OCD | 1 |
| Foiatto, JC | 1 |
| Czeczko, NG | 1 |
| Wietzikoski, EG | 1 |
| Malafaia, O | 1 |
| Brenny, T | 1 |
| Oliveira, AM | 1 |
| Gomes, RP | 1 |
| Tucci Junior, S | 1 |
| Carvalho, RM | 1 |
| Celini, FM | 1 |
| Cologna, AJ | 1 |
| Suaid, HJ | 1 |
| Tirapelli, LF | 1 |
| Martins, AC | 1 |
| Malyukova, I | 1 |
| Murray, KF | 1 |
| Zhu, C | 1 |
| Boedeker, E | 1 |
| Kane, A | 1 |
| Patterson, K | 1 |
| Peterson, JR | 1 |
| Donowitz, M | 1 |
| Kovbasnjuk, O | 1 |
| Feifel, D | 1 |
| Shilling, PD | 1 |
| Melendez, G | 1 |
| Sonibare, MA | 1 |
| Umukoro, S | 1 |
| Shonibare, ET | 1 |
| Bankstahl, M | 1 |
| Bankstahl, JP | 1 |
| Bloms-Funke, P | 1 |
| Löscher, W | 1 |
| Villarreal, CF | 1 |
| Funez, MI | 1 |
| Cunha, Fde Q | 1 |
| Parada, CA | 1 |
| Ferreira, SH | 1 |
| Bosch-Morell, F | 1 |
| Romá, J | 1 |
| Marín, N | 1 |
| Romero, B | 1 |
| Rodriguez-Galietero, A | 1 |
| Johnsen-Soriano, S | 1 |
| Díaz-Llopis, M | 1 |
| Romero, FJ | 1 |
| Sader, AA | 1 |
| Barbieri-Neto, J | 1 |
| Sader, SL | 1 |
| Mazzetto, SA | 1 |
| Alves, P | 1 |
| Vanni, JC | 1 |
| Takakura, N | 1 |
| Sato, Y | 1 |
| Ishibashi, H | 2 |
| Oshima, H | 1 |
| Uchida, K | 1 |
| Yamaguchi, H | 2 |
| Can, C | 1 |
| Demirci, B | 1 |
| Uysal, A | 1 |
| Akçay, YD | 1 |
| Koşay, S | 1 |
| Leyva, E | 1 |
| Campos, B | 1 |
| Lara, M | 1 |
| Ibáñez, M | 1 |
| Farfán, N | 1 |
| Orozco, H | 1 |
| Hernández-Pando, R | 1 |
| Schilling, G | 1 |
| Savonenko, AV | 1 |
| Coonfield, ML | 1 |
| Morton, JL | 1 |
| Vorovich, E | 1 |
| Gale, A | 1 |
| Neslon, C | 1 |
| Chan, N | 1 |
| Eaton, M | 1 |
| Fromholt, D | 1 |
| Ross, CA | 1 |
| Borchelt, DR | 1 |
| Tada, M | 1 |
| Shirakawa, K | 1 |
| Matsuoka, N | 1 |
| Mutoh, S | 1 |
| Piccinato, CE | 1 |
| Salles Roselino, JE | 1 |
| Massuda, CA | 1 |
| Cherri, J | 1 |
| Hironaka, N | 1 |
| Pillai, A | 1 |
| Parikh, V | 1 |
| Terry, AV | 1 |
| Mahadik, SP | 1 |
| Sulaiman, AA | 1 |
| Al-Shawi, NN | 1 |
| Jwaied, AH | 1 |
| Mahmood, DM | 1 |
| Hussain, SA | 1 |
| Hisajima, T | 1 |
| Hu, W | 1 |
| Nishiyama, Y | 1 |
| Bishnoi, M | 1 |
| Chopra, K | 1 |
| Kulkarni, SK | 1 |
| Lange, S | 1 |
| Lonnroth, I | 1 |
| Glassman, RB | 1 |
| Glassman, HN | 1 |
| Burke, RE | 2 |
| Fahn, S | 2 |
| Klawans, HL | 4 |
| Goetz, CG | 2 |
| Carvey, P | 3 |
| Nakano, M | 1 |
| Tani, E | 1 |
| Fukumori, T | 1 |
| Yokota, M | 1 |
| Obata, T | 1 |
| Morgenstern, R | 1 |
| Fink, H | 1 |
| Oelssner, W | 1 |
| Atadzhanov, M | 1 |
| Chien, KR | 1 |
| Crie, JS | 1 |
| Decker, RS | 1 |
| Wildenthal, K | 1 |
| Maguire, HC | 2 |
| Kaidbey, K | 1 |
| Hitri, A | 1 |
| Nausieda, PA | 1 |
| Weiner, WJ | 1 |
| Rotrosen, J | 1 |
| Stanley, M | 1 |
| Kuhn, C | 1 |
| Wazer, D | 1 |
| Gershon, S | 1 |
| Nunnally, RL | 1 |
| Bottomley, PA | 1 |
| Ishikawa, M | 1 |
| Ozaki, M | 1 |
| Takayanagi, Y | 1 |
| Sasaki, K | 1 |
| Kyle, DE | 1 |
| Milhous, WK | 1 |
| Rossan, RN | 1 |
| Gatti, S | 1 |
| Faggioni, R | 1 |
| Echtenacher, B | 1 |
| Ghezzi, P | 1 |
| Mize, NK | 1 |
| Buttery, M | 1 |
| Ruis, N | 1 |
| Leung, I | 1 |
| Cormier, M | 1 |
| Daddona, P | 1 |
| Jansen, MJ | 1 |
| Hendriks, T | 1 |
| Knapen, MF | 1 |
| van Kempen, LC | 1 |
| van der Meer, JW | 1 |
| Goris, RJ | 1 |
| Takata, Y | 1 |
| Kurihara, J | 1 |
| Suzuki, S | 1 |
| Okubo, Y | 1 |
| Kato, H | 1 |
| Aygit, AC | 1 |
| Ayhan, MS | 1 |
| Demiralay, A | 1 |
| Yildirim, I | 1 |
| Nisijima, K | 1 |
| Yoshino, T | 1 |
| Yui, K | 1 |
| Katoh, S | 1 |
| Wright, MC | 1 |
| Issa, R | 1 |
| Smart, DE | 1 |
| Trim, N | 1 |
| Murray, GI | 1 |
| Primrose, JN | 1 |
| Arthur, MJ | 1 |
| Iredale, JP | 1 |
| Mann, DA | 1 |
| Heros, RC | 1 |
| Zervas, NT | 1 |
| Negoro, M | 1 |
| Ljunggren, B | 1 |
| Möller, H | 1 |
| Ros, E | 1 |
| Small, DM | 1 |
| Carey, MC | 1 |
| Akin, FJ | 1 |
| Rose, AP | 1 |
| Chamness, TW | 1 |
| Marlowe, E | 1 |
| Elias, E | 1 |
| Boyer, JL | 1 |
| Anderson, RJ | 1 |
| Raines, A | 1 |
| Stoff, DM | 1 |
| Moja, EA | 1 |
| Gillin, JC | 1 |
| Wyatt, RJ | 1 |
| Wada, JA | 1 |
| Benhar, E | 1 |
| Montastruc, JL | 1 |
| Moreno-González, A | 1 |
| Cotonat, J | 1 |
| Moran, EC | 1 |
| McKinney, WT | 3 |
| Duvoisin, RC | 2 |
| Kaltwasser, K | 1 |
| Kleinau, H | 1 |
| Pankow, D | 1 |
| Ponsold, W | 1 |
| Strahl, U | 1 |
| Takeuchi, K | 1 |
| Okabe, S | 1 |
| Takagi, K | 1 |
| Vargas, I | 1 |
| Kawada, ME | 1 |
| Nagamoto, Y | 1 |
| Arita, M | 1 |
| Saikawa, T | 1 |
| Sassin, JF | 1 |
| Sayers, AC | 1 |
| Bürki, HR | 1 |
| Ruch, W | 1 |
| Asper, H | 1 |
| Arushanian, EB | 1 |
| Kong, D | 1 |
| Kasner, L | 1 |
| Chan, CC | 1 |
| Cordella-Miele, E | 1 |
| Gery, I | 1 |
| Seif el Nasr, M | 1 |
| Nuglisch, J | 1 |
| Krieglstein, J | 1 |
| Dai, JL | 1 |
| Xu, SF | 1 |
| Tan, U | 1 |
| Gepdíremen, A | 1 |
| Banoglu, N | 1 |
| Kutlu, N | 1 |
| Zienowicz, RJ | 1 |
| Thomas, BA | 1 |
| Kurtz, WH | 1 |
| Orgel, MG | 1 |
| Miyamoto, K | 1 |
| Cox, E | 2 |
| Cools, V | 2 |
| Houvenaghel, A | 2 |
| Tanner, CM | 1 |
| Jung, W | 1 |
| Gebhardt, R | 1 |
| Robenek, H | 1 |
| Rupniak, NM | 1 |
| Jenner, P | 1 |
| Marsden, CD | 2 |
| Vezzani, A | 1 |
| Wu, HQ | 1 |
| Tullii, M | 1 |
| Samanin, R | 1 |
| Manzanares, J | 1 |
| Cantón, R | 1 |
| Grande, C | 1 |
| Benedi, J | 1 |
| Zaragozá, F | 1 |
| Miller, JD | 1 |
| Brizzee, KR | 1 |
| Geter, RK | 1 |
| Winters, RR | 1 |
| Puckett, CL | 1 |
| Giudici, PA | 1 |
| Gomita, Y | 1 |
| Ogawa, N | 1 |
| Ueki, S | 1 |
| Wyllie, RG | 1 |
| Hill, GS | 1 |
| Murray, G | 1 |
| Ramsden, PW | 1 |
| Heptinstall, RH | 1 |
| Young, LD | 1 |
| Suomi, SJ | 1 |
| Davis, JM | 1 |
| Poirier, LJ | 1 |
| Carlsson, A | 1 |
| Wiley, MK | 1 |
| Pearlmutter, AF | 1 |
| Miller, RE | 1 |
| Martin, L | 1 |
| Anton, AH | 1 |
| Petri, G | 1 |
| Pórszász, J | 1 |
| Pórszász-Gibiszer, K | 1 |
| McKenzie, GM | 1 |
| Gordon, RJ | 1 |
| Viik, K | 1 |
| Krsiak, M | 1 |
| Goldstein, DB | 1 |
| Mawson, AR | 1 |
| Rubovits, R | 1 |
| Benkert, O | 1 |
| Hippius, H | 1 |
| Dinsmoor, JA | 1 |
| Bonbright, JC | 1 |
| Lilie, DR | 1 |
| Popenenkova, AZ | 1 |
| Romanovskaia, MG | 1 |
| Feola, M | 1 |
| Haiderer, O | 1 |
| Kennedy, JH | 1 |
| Klos, I | 1 |
| Schwarz, KJ | 1 |
| Levij, IS | 1 |
| Polliack, A | 1 |
| Forrest, IS | 1 |
| Kosek, JC | 1 |
| Aber, RC | 1 |
| Serra, MT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Controlled Trial of Adjunctive Siltuximab in Schizophrenia[NCT02796859] | Phase 1/Phase 2 | 30 participants (Anticipated) | Interventional | 2016-05-31 | Recruiting | ||
| A Randomised, Controlled Trial of Losartan as an Anti-fibrotic Agent in Non-alcoholic Steatohepatitis[NCT01051219] | Phase 3 | 45 participants (Actual) | Interventional | 2011-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
12 reviews available for chlorpromazine and Disease Models, Animal
| Article | Year |
|---|---|
Employing proteomics to unravel the molecular effects of antipsychotics and their role in schizophrenia.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Brain; Chlorpromazine; Clozapine; Disease Models, Anima | 2016 |
[Overview of behavioral pharmacology: what does animal behavior tell us?].
Topics: Animals; Avoidance Learning; Behavior, Animal; Chlorpromazine; Conditioning, Operant; Disease Models | 2005 |
[Modeling parkinsonism (review)].
Topics: Aluminum; Animals; Carbachol; Cats; Caudate Nucleus; Chlorides; Chlorpromazine; Disease Models, Anim | 1982 |
Cerebral vasospasm.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Angiotensin II; Animals; Blood Platelets; | 1976 |
Mechanisms of intrahepatic cholestasis.
Topics: Animals; Bile; Bile Acids and Salts; Cell Membrane Permeability; Chlorpromazine; Cholestasis; Cytosk | 1979 |
Pharmacological prophylaxis in the kindling model of epilepsy.
Topics: Amygdala; Anesthetics, Local; Animals; Antidepressive Agents, Tricyclic; Atropine; Aziridines; Carba | 1977 |
Drug-induced dyskinesia in monkeys.
Topics: Amphetamine; Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Azides; Carbachol; Caudate Nucle | 1975 |
Acute dystonia induced by neuroleptic drugs.
Topics: Acute Disease; alpha-Methyltyrosine; Animals; Antipsychotic Agents; Brain; Chlorpromazine; Disease M | 1986 |
Animal models in psychiatry.
Topics: Age Factors; Amines; Animals; Avoidance Learning; Brain; Cats; Chlorpromazine; Depression; Disease M | 1974 |
Nervous mechanisms involved in experimentally induced extrapyramidal disturbances.
Topics: Animals; Basal Ganglia Diseases; Benztropine; Brain; Cats; Caudate Nucleus; Cerebellar Nuclei; Chlor | 1974 |
Biochemical and pharmacological aspects of Parkinsonism.
Topics: Animals; Blood-Brain Barrier; Brain; Central Nervous System; Chemoreceptor Cells; Chlorpromazine; Co | 1972 |
Anorexia nervosa and the regulation of intake: a review.
Topics: Adolescent; Adult; Amygdala; Androgens; Animals; Anorexia Nervosa; Appetite Regulation; Brain; Child | 1974 |
109 other studies available for chlorpromazine and Disease Models, Animal
| Article | Year |
|---|---|
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Dopamine relieves inflammatory responses through the D2 receptor after electroacupuncture at ST36 in a mouse model of chronic obstructive pulmonary disease.
Topics: Animals; Anti-Inflammatory Agents; Chlorpromazine; Cytokines; Disease Models, Animal; Dopamine; Elec | 2023 |
Establishing a Mouse Model of Chlorpromazine-Induced Corneal Trigeminal Denervation.
Topics: Animals; Chlorpromazine; Cornea; Culture Media, Conditioned; Denervation; Disease Models, Animal; Mi | 2023 |
Effect of M. chamomilla L. tea on chlorpromazine induced catalepsy: A neuroprotective study.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Brain; Catalepsy; Chlorpromazine; Disease Models, A | 2020 |
Drug induces depression-like phenotypes and alters gene expression profiles in Drosophila.
Topics: Animals; Chlorpromazine; Depressive Disorder, Major; Disease Models, Animal; Dose-Response Relations | 2017 |
Extract of Synedrella nodiflora (L) Gaertn exhibits antipsychotic properties in murine models of psychosis.
Topics: Animals; Antipsychotic Agents; Apomorphine; Asteraceae; Behavior, Animal; Catalepsy; Chlorpromazine; | 2017 |
Phenothiazines Enhance Mild Hypothermia-induced Neuroprotection via PI3K/Akt Regulation in Experimental Stroke.
Topics: Animals; Antipsychotic Agents; Chlorpromazine; Combined Modality Therapy; Disease Models, Animal; Hy | 2017 |
Advantages of the Alpha-lipoic Acid Association with Chlorpromazine in a Model of Schizophrenia Induced by Ketamine in Rats: Behavioral and Oxidative Stress evidences.
Topics: Animals; Antioxidants; Antipsychotic Agents; Chlorpromazine; Disease Models, Animal; Drug Therapy, C | 2018 |
Dysregulation of miR-155-5p and miR-200-3p and the Anti-Non-Bilayer Phospholipid Arrangement Antibodies Favor the Development of Lupus in Three Novel Murine Lupus Models.
Topics: Adaptor Proteins, Vesicular Transport; Animals; Antibody Formation; Chlorpromazine; Disease Models, | 2017 |
Anticataleptic activity of Zamzam water in chlorpromazine induced animal model of Parkinson disease.
Topics: Animals; Brain; Carbidopa; Catalepsy; Chlorpromazine; Disease Models, Animal; Drug Combinations; Hyd | 2018 |
Na
Topics: Animals; Chlorpromazine; Disease Models, Animal; Dopamine D2 Receptor Antagonists; Genes, fos; Halop | 2019 |
Self-Nanoemulsifying Drug Delivery System (SNEDDS) for Improved Oral Bioavailability of Chlorpromazine: In Vitro and In Vivo Evaluation.
Topics: Administration, Oral; Animals; Biological Availability; Chlorpromazine; Disease Models, Animal; Drug | 2019 |
Maternal immune activation leads to age-related behavioral and immunological changes in male rat offspring - the effect of antipsychotic drugs.
Topics: Age Factors; Aging; Animals; Antipsychotic Agents; Behavior, Animal; Cell Proliferation; Cells, Cult | 2012 |
Characteristic molecular and proteomic signatures of drug-induced liver injury in a rat model.
Topics: Animals; Biomarkers; Carbamazepine; Chemical and Drug Induced Liver Injury; Chlorpromazine; Disease | 2015 |
Nonbilayer Phospholipid Arrangements Are Toll-Like Receptor-2/6 and TLR-4 Agonists and Trigger Inflammation in a Mouse Model Resembling Human Lupus.
Topics: Animals; Autoantibodies; Chlorpromazine; Cytokines; Diglycerides; Disease Models, Animal; Female; Fl | 2015 |
A Novel Murine Candidiasis Model with Severe Colonization in the Stomach Induced by N-acetylglucosamine-treatment and Its Scoring System Based on Local Characteristic Stomach Symptoms.
Topics: Acetylglucosamine; Animals; Candida albicans; Candidiasis; Chlorpromazine; Disease Models, Animal; D | 2015 |
Electroencephalographic study of chlorpromazine alone or combined with alpha-lipoic acid in a model of schizophrenia induced by ketamine in rats.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Brain; Chlorpromazine; Disease Models, Animal; | 2017 |
Influence of chlorpromazine on renal histology of rats submitted to ischemia and reperfusion injury.
Topics: Animals; Chlorpromazine; Disease Models, Animal; Ischemia; Ischemic Preconditioning; Kidney; Kidney | 2016 |
Renal ischemia and reperfusion injury: influence of chorpromazine on renal function and lipid peroxidation.
Topics: Animals; Biomarkers; Chlorpromazine; Creatinine; Disease Models, Animal; Dopamine Antagonists; Ische | 2008 |
Macropinocytosis in Shiga toxin 1 uptake by human intestinal epithelial cells and transcellular transcytosis.
Topics: Actins; Animals; cdc42 GTP-Binding Protein; Cell Line; Cell Membrane; Chlorpromazine; Clathrin; Dise | 2009 |
Further characterization of the predictive validity of the Brattleboro rat model for antipsychotic efficacy.
Topics: Animals; Antipsychotic Agents; Chlorpromazine; Diazepam; Disease Models, Animal; Female; Imipramine; | 2011 |
Antipsychotic property of aqueous and ethanolic extracts of Lonchocarpus cyanescens (Schumach and Thonn.) Benth. (Fabaceae) in rodents.
Topics: Amphetamine; Animals; Antipsychotic Agents; Behavior, Animal; Catalepsy; Chlorpromazine; Chromatogra | 2012 |
Striking differences in proconvulsant-induced alterations of seizure threshold in two rat models.
Topics: Animals; Anticonvulsants; Caffeine; Central Nervous System Stimulants; Chlorpromazine; Convulsants; | 2012 |
The long-lasting sensitization of primary afferent nociceptors induced by inflammation involves prostanoid and dopaminergic systems in mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Biphenyl Compounds; Carrageenan; Central Nervous S | 2013 |
Role of oxygen and nitrogen species in experimental uveitis: anti-inflammatory activity of the synthetic antioxidant ebselen.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Azoles; Chlorpromazine; Disease Models, Animal; Enz | 2002 |
The protective action of chlorpromazine on the spinal cord of rabbits submitted to ischemia and reperfusion is dose-dependent.
Topics: Animals; Biopsy, Needle; Brain Ischemia; Chlorpromazine; Disease Models, Animal; Dose-Response Relat | 2002 |
A novel murine model of oral candidiasis with local symptoms characteristic of oral thrush.
Topics: Amphotericin B; Animals; Antifungal Agents; Candida albicans; Candidiasis, Oral; Chlorpromazine; Dis | 2003 |
Contradictory effects of chlorpromazine on endothelial cells in a rat model of endotoxic shock in association with its actions on serum TNF-alpha levels and antioxidant enzyme activities.
Topics: Analysis of Variance; Animals; Antioxidants; Aorta; Catalase; Chlorpromazine; Disease Models, Animal | 2003 |
Antibodies to non-bilayer phospholipid arrangements induce a murine autoimmune disease resembling human lupus.
Topics: Animals; Anti-Arrhythmia Agents; Antipsychotic Agents; Autoantibodies; Autoimmune Diseases; Chlorpro | 2004 |
Environmental, pharmacological, and genetic modulation of the HD phenotype in transgenic mice.
Topics: Acetamides; Animals; Celecoxib; Chlorpromazine; Coenzymes; Cyclooxygenase Inhibitors; Disease Models | 2004 |
Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Administration, Oral; Animals; Antipsychotic Agents; Basal G | 2004 |
Lack of chlorpromazine effect on skeletal muscle metabolism after ischemia and a short reperfusion period.
Topics: Animals; Chlorpromazine; Disease Models, Animal; Dogs; Glycogen; Hydrogen-Ion Concentration; Ischemi | 2004 |
Long-term antipsychotic treatments and crossover studies in rats: differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain; Chlorpromazine; Clozapine; Cross-Over Studies | 2007 |
Protective effect of melatonin against chlorpromazine-induced liver disease in rats.
Topics: Animals; Antioxidants; Chemical and Drug Induced Liver Injury; Chlorpromazine; Disease Models, Anima | 2006 |
A murine model of esophageal candidiasis with local characteristic symptoms.
Topics: Administration, Oral; Animals; Antifungal Agents; Candida albicans; Candidiasis; Chlorpromazine; Dis | 2007 |
U-74500A (lazaroid), a 21-aminosteroid attenuates neuroleptic-induced orofacial dyskinesia.
Topics: Animals; Antioxidants; Antipsychotic Agents; Chlorpromazine; Disease Models, Animal; Dyskinesia, Dru | 2007 |
Hypersecretion induced by Escherichia coli heat-stable enterotoxin in intestinal loops in rat and mouse.
Topics: Animals; Bacterial Toxins; Bile; Body Fluids; Chlorpromazine; Cyclic GMP; Disease Models, Animal; En | 1983 |
Oral dyskinesia in brain-damaged rats withdrawn from a neuroleptic: implication for models of tardive dyskinesia.
Topics: Amphetamine; Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Brain; Chlorpromazine; Di | 1980 |
Electroencephalographic studies of chlorpromazine methiodide and somatostatin-induced barrel rotation in rats.
Topics: Animals; Behavior, Animal; Chlorpromazine; Disease Models, Animal; Dystonia; Electroencephalography; | 1983 |
Animal models of tardive dyskinesias.
Topics: Animals; Antipsychotic Agents; Apomorphine; Chlorpromazine; Disease Models, Animal; Dyskinesia, Drug | 1983 |
Effects of chlorpromazine on experimental delayed cerebral vasospasm.
Topics: Animals; Basilar Artery; Blood; Cerebral Angiography; Chlorpromazine; Cisterna Magna; Disease Models | 1984 |
Intrahepatic cholestasis and hyperbilirubinemia in ethynyl estradiol and chlorpromazine-treated rats.
Topics: Animals; Chlorpromazine; Cholestasis, Intrahepatic; Disease Models, Animal; Ethinyl Estradiol; Femal | 1983 |
LSD-potentiated apomorphine hypermotility: a model for differentiating antipsychotic drugs.
Topics: Animals; Apomorphine; Chlorpromazine; Clozapine; Disease Models, Animal; Drug Antagonism; Haloperido | 1983 |
Influence of chlorpromazine on lysosomal alterations during myocardial ischaemia.
Topics: Animals; Cathepsin D; Cathepsins; Chlorpromazine; Coronary Disease; Disease Models, Animal; Lysosome | 1983 |
Experimental photoallergic contact dermatitis: a mouse model.
Topics: Animals; Chlorpromazine; Coumarins; Dermatitis, Contact; Disease Models, Animal; Lymph Nodes; Mice; | 1982 |
Correlation between daily dosage of chlorpromazine and subsequent supersensitivity.
Topics: Animals; Apomorphine; Behavior, Animal; Chlorpromazine; Corpus Striatum; Disease Models, Animal; Dop | 1980 |
Experimental dystonia induced by quaternary-chlorpromazine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Chlorpromazine; Corpus Striatum; Disease | 1980 |
Assessment of pharmacological treatment of myocardial infarction by phosphorus-31 NMR with surface coils.
Topics: Animals; Chlorpromazine; Coronary Circulation; Disease Models, Animal; Magnetic Resonance Spectrosco | 1981 |
Protection against cisplatin lethality and renal toxicity by chlorpromazine in mice.
Topics: Animals; Chlorpromazine; Cisplatin; Disease Models, Animal; Drug Therapy, Combination; Kidney; Letha | 1994 |
Reversal of Plasmodium falciparum resistance to chloroquine in Panamanian Aotus monkeys.
Topics: Animals; Aotus trivirgatus; Calcium Channel Blockers; Chloroquine; Chlorpromazine; Cyproheptadine; D | 1993 |
Role of tumour necrosis factor and reactive oxygen intermediates in lipopolysaccharide-induced pulmonary oedema and lethality.
Topics: Acetylcysteine; Animals; Antibodies, Monoclonal; Bronchoalveolar Lavage Fluid; Chlorpromazine; Dexam | 1993 |
Antiflammin 1 peptide delivered non-invasively by iontophoresis reduces irritant-induced inflammation in vivo.
Topics: Administration, Cutaneous; Animals; Anti-Inflammatory Agents, Non-Steroidal; Chlorpromazine; Dermati | 1997 |
Chlorpromazine down-regulates tumor necrosis factor-alpha and attenuates experimental multiple organ dysfunction syndrome in mice.
Topics: Animals; Chlorpromazine; Disease Models, Animal; Down-Regulation; Drug Administration Schedule; Immu | 1998 |
A rabbit model for evaluation of chlorpromazine-induced orthostatic hypotension.
Topics: Adrenergic alpha-Antagonists; Animals; Antipsychotic Agents; Aorta; Blood Pressure; Cardiac Output; | 1999 |
Vascular effects of epinephrine, lisinopril, and chlorpromazine in diabetic and non-diabetic rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Chlorpromazine; Diabetes Mellitus, Experimental; | 1999 |
Potent serotonin (5-HT)(2A) receptor antagonists completely prevent the development of hyperthermia in an animal model of the 5-HT syndrome.
Topics: 5-Hydroxytryptophan; Animals; Anterior Hypothalamic Nucleus; Antidepressive Agents; Body Temperature | 2001 |
Gliotoxin stimulates the apoptosis of human and rat hepatic stellate cells and enhances the resolution of liver fibrosis in rats.
Topics: Animals; Anti-Allergic Agents; Apoptosis; Calcium; Carbon Tetrachloride; Chlorpromazine; Collagen; C | 2001 |
Phototoxic reaction to long-term low-dose administration of chlorpromazine in mice.
Topics: Animals; Chlorpromazine; Disease Models, Animal; Erythema; Female; Mice; Photosensitivity Disorders; | 1978 |
Effects of chlorpromazine hydrochloride on bile salt synthesis, bile formation and biliary lipid secretion in the rhesus monkey: a model for chlorpromazine-induced cholestasis.
Topics: Animals; Bile; Bile Acids and Salts; Chlorpromazine; Cholestasis; Disease Models, Animal; Dose-Respo | 1979 |
Sunscreen protection against drug-induced phototoxicity in animal models.
Topics: 4-Aminobenzoic Acid; Aminobenzoates; Animals; Chlorpromazine; Demeclocycline; Disease Models, Animal | 1979 |
Suppression of decerebrate rigidity by phenytoin and chlorpromazine.
Topics: Animals; Cats; Chlorpromazine; Decerebrate State; Disease Models, Animal; Dose-Response Relationship | 1976 |
Disruption of conditioned avoidance behavior by n,n-dimethyltryptamine (DMT) and stereotype by beta-phenylethylamine (PEA): animal models of attentional defects in schizophrenia.
Topics: Animals; Attention; Avoidance Learning; Behavior; Chlorpromazine; Conditioning, Operant; Disease Mod | 1978 |
The olive babbon (Papio anubis) as an animal model for research in affective disorders of man.
Topics: Affective Symptoms; Animals; Biogenic Amines; Brain; Chlorpromazine; Disease Models, Animal; Haplorh | 1977 |
[Effect of chlorpromazine on hypertension by desinhibition in dogs: comparison of intravenous and intracisternal administration (author's transl)].
Topics: Animals; Blood Pressure; Chlorpromazine; Cisterna Magna; Disease Models, Animal; Dogs; Heart Rate; H | 1978 |
Effects of chlorpromazine on the vertical chamber syndrome in rhesus monkeys.
Topics: Animals; Chlorpromazine; Depression; Disease Models, Animal; Haplorhini; Humans; Mental Disorders; S | 1975 |
Parkinsonism: animal analogues of the human disorder.
Topics: Animals; Butyrophenones; Chlorpromazine; Disease Models, Animal; Haplorhini; Hydroxydopamines; Levod | 1976 |
[Hypothermia and carbon monoxide poisoning].
Topics: Animals; Body Temperature; Carbon Monoxide Poisoning; Chlorpromazine; Disease Models, Animal; Fever; | 1977 |
A new model of stress ulcer in the rat with pylorus ligation and its pathogenesis.
Topics: Amylopectin; Animals; Atropine; Bicarbonates; Chlorpromazine; Disease Models, Animal; Gastric Mucosa | 1976 |
Adrenal and liver participation in the rat's post-stress diabetic response.
Topics: Adrenal Glands; Adrenalectomy; Animals; Blood Glucose; Blood Proteins; Chlorpromazine; Diabetes Mell | 1976 |
The prolongation of QRS-duration resulting from delayed recovery of ventricular excitability. A new mechanism for intraventricular conduction disturbance. A preliminary note.
Topics: Animals; Arrhythmias, Cardiac; Chlorpromazine; Disease Models, Animal; Dogs; Electrocardiography; He | 1976 |
Neuroleptic-induced hypersensitivity of striatal dopamine receptors in the rat as a model of tardive dyskinesias. Effects of clozapine, haloperidol, loxapine and chlorpromazine.
Topics: Animals; Apomorphine; Chlorpromazine; Clozapine; Corpus Striatum; Dibenzazepines; Dibenzoxazepines; | 1975 |
[The phenomenon of experimental motor retardation as one of the manifestations of the Parkinsonian syndrome].
Topics: Amphetamine; Animals; Catecholamines; Cats; Caudate Nucleus; Chlorpromazine; Dihydroergotoxine; Dise | 1975 |
[Preliminary study of changes in plasma prostaglandin E1 in rats with experimental "schizophrenia"].
Topics: Alprostadil; Animals; Chlorpromazine; Dextroamphetamine; Disease Models, Animal; Female; Male; Rats; | 1992 |
The effect of chlorpromazine on endotoxin-induced uveitis in the Lewis rat.
Topics: Animals; Aqueous Humor; Bacterial Toxins; Chlorpromazine; Disease Models, Animal; Endotoxins; Entero | 1992 |
Prevention of ischemia-induced cerebral hypothermia by controlling the environmental temperature.
Topics: Animals; Body Temperature; Body Temperature Regulation; Brain; Brain Ischemia; Chlorpromazine; Disea | 1992 |
The attenuation effect of chlorpromazine on electro-acupuncture analgesia: involvement of dopamine system.
Topics: Acupuncture Analgesia; Animals; Biogenic Monoamines; Chlorpromazine; Combined Modality Therapy; Dise | 1991 |
Intermittent tremor-bursts induced by chlorpromazine and pentobarbitone in guinea pigs: a new tremor model.
Topics: Acoustic Stimulation; Animals; Biperiden; Chlorpromazine; Disease Models, Animal; Guinea Pigs; Muscl | 1991 |
A multivariate approach to the treatment of peripheral nerve transection injury: the role of electromagnetic field therapy.
Topics: Analysis of Variance; Animals; Chlorpromazine; Disease Models, Animal; Electromagnetic Fields; Pilot | 1991 |
Conditioned drug effects of pimozide, haloperidol and chlorpromazine on methamphetamine-induced behavior.
Topics: Animals; Arousal; Chlorpromazine; Conditioning, Classical; Disease Models, Animal; Dose-Response Rel | 1990 |
Effect of chlorpromazine on experimental diarrhoea in just-weaned piglets.
Topics: Animals; Chlorpromazine; Diarrhea; Disease Models, Animal; Escherichia coli Infections; Female; Gast | 1989 |
Effect of antisecretory drugs on experimentally induced weanling diarrhoea in piglets.
Topics: Animals; Animals, Newborn; Chlorpromazine; Clonidine; Diarrhea; Disease Models, Animal; Escherichia | 1989 |
The pathophysiology of tardive dyskinesia.
Topics: Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Chlorpromazine; Corpus Striatum; Disea | 1985 |
Primary culture of rat hepatocytes as a model system of canalicular development, biliary secretion, and intrahepatic cholestasis. V. Disturbance of the cellular membrane and bile canalicular ultrastructure induced by chlorpromazine.
Topics: Animals; Bile; Bile Ducts, Intrahepatic; Cell Membrane; Cell Survival; Cells, Cultured; Chlorpromazi | 1985 |
An evaluation of sustained postural abnormalities in rats induced by intracerebro-ventricular injection of chlorpromazine methiodide or somatostatin as models of dystonia.
Topics: Animals; Cerebral Ventricles; Chemical Phenomena; Chemistry; Chlorpromazine; Disease Models, Animal; | 1988 |
Anticonvulsant drugs effective against human temporal lobe epilepsy prevent seizures but not neurotoxicity induced in rats by quinolinic acid: electroencephalographic, behavioral and histological assessments.
Topics: Animals; Anticonvulsants; Behavior, Animal; Carbamazepine; Chlorpromazine; Diazepam; Disease Models, | 1986 |
Amphetamine and chlorpromazine modify cerebral insulin levels in rats.
Topics: Amphetamine; Animals; Brain; Chlorpromazine; Disease Models, Animal; Female; Insulin; Rats; Rats, In | 1988 |
The anti-emetic properties of 1-sulpiride in a ground-based model of space motion sickness.
Topics: Animals; Antiemetics; Chlorpromazine; Disease Models, Animal; Domperidone; Female; Male; Motion Sick | 1987 |
Resolution of experimental microvascular spasm and improvement in anastomotic patency by direct topical agent application.
Topics: Administration, Topical; Animals; Chlorpromazine; Disease Models, Animal; Drug Evaluation; Epinephri | 1986 |
Experimental photoallergy to systemic drugs.
Topics: Animals; Chlorpromazine; Disease Models, Animal; Hypersensitivity, Delayed; Injections, Intraperiton | 1985 |
Effects of psychotropic drugs on discrimination conditioning in olfactory bulbectomized rats.
Topics: Amitriptyline; Animals; Avoidance Learning; Chlordiazepoxide; Chlorpromazine; Discrimination Learnin | 1985 |
Experimental papillary necrosis of the kidney. 3. Effects of reserpine and other pharmacologic agents on the lesion.
Topics: Adenosine Triphosphatases; Animals; Blood Pressure; Bromine; Catecholamines; Chlorpromazine; Colorin | 1972 |
Chlorpromazine treatment of disturbed monkeys.
Topics: Administration, Intranasal; Aggression; Aging; Animals; Behavior, Animal; Chlorpromazine; Circadian | 1973 |
Decreased adrenal sensitivity to ACTH in the vasopressin-deficient (Brattleboro) rat.
Topics: Adrenal Glands; Adrenocorticotropic Hormone; Animals; Chlorpromazine; Corticotropin-Releasing Hormon | 1974 |
Toxicity of acids and bases after intraperitoneal injection.
Topics: Acetates; Acids; Alkalies; Analgesics; Anesthetics, Local; Animals; Anti-Bacterial Agents; Body Temp | 1970 |
The action of sympatholytic drugs in experimental intestinal paralysis.
Topics: Anesthesia; Animals; Cats; Chlorpromazine; Disease Models, Animal; Ganglionic Blockers; Gastrointest | 1971 |
Some biochemical and behavioural correlates of a possible animal model of human hyperkinetic syndromes.
Topics: Amphetamine; Animals; Atropine; Behavior, Animal; Catecholamines; Cats; Caudate Nucleus; Chlorpromaz | 1972 |
Proceedings: Isolation-induced timidity in mice as a measure of anxiolytic activity of drugs.
Topics: Animals; Anxiety Disorders; Barbiturates; Chlordiazepoxide; Chlorpromazine; Dextroamphetamine; Diaze | 1974 |
Quantitative study of alcohol withdrawal signs in mice.
Topics: Alcoholism; Animals; Barbiturates; Behavior, Animal; Chlorpromazine; Diazepam; Disease Models, Anima | 1973 |
An experimental model of tardive dyskinesia.
Topics: Amphetamine; Animals; Apomorphine; Behavior, Animal; Chlorpromazine; Corpus Striatum; Disease Models | 1972 |
[Significance of pharmaco-psychiatric findings for basic biological psychiatric research].
Topics: Antidepressive Agents; Bipolar Disorder; Catecholamines; Chlorpromazine; Deficiency Diseases; Diseas | 1973 |
Reversal of reserpine-induced bradykinesia by alpha-methyldopa--new light on its modus operandi.
Topics: Animals; Carbidopa; Chlorpromazine; Dihydroxyphenylalanine; Disease Models, Animal; Disulfiram; Dose | 1974 |
A controlled comparison of drug effects on escape from conditioned aversive stimulation ("anxiety") and from continuous shock.
Topics: Animals; Anxiety; Avoidance Learning; Chlordiazepoxide; Chlorpromazine; Disease Models, Animal; Esca | 1971 |
[Effect of aminazin, chloracizin and vetrazine on catecholamines and their metabolism in rats infected with pneumococcus].
Topics: Animals; Catecholamines; Chlorpromazine; Disease Models, Animal; Hydrazines; Methods; Monoamine Oxid | 1971 |
Experimental graded "pump failure" of the left ventricle.
Topics: Animals; Aorta, Thoracic; Blood Flow Velocity; Blood Pressure; Carbon Dioxide; Cardiac Output; Cardi | 1971 |
[Lysis of mechanically produced spasms of small arteries through local drug administration].
Topics: Animals; Chlorpromazine; Disease Models, Animal; Lidocaine; Rabbits; Renal Artery; Spasm; Vascular D | 1971 |
[Experimental studies on sulfanilamide and chlorpromazine photoallergy].
Topics: Allergens; Animals; Chlorpromazine; Chromatography, Paper; Disease Models, Animal; Drug Hypersensiti | 1969 |
Inhibition of chemical carcinogenesis in the hamster cheek pouch by topical chlorpromazine.
Topics: Animals; Benz(a)Anthracenes; Chlorpromazine; Cricetinae; Disease Models, Animal; Mouth Mucosa; Neopl | 1970 |
Rabbit as a model for chlorpromazine-induced hyperpigmentation of the skin.
Topics: Animals; Chlorpromazine; Disease Models, Animal; Pigmentation Disorders; Rabbits; Radiation Effects; | 1970 |